EUVIMEDEUVIMED entdecken
QuerschnittstudieOpen Access · CC BY 3.0

Prevalence of hepatitis B virus infection among general population of Armenia in 2021 and factors associated with it: a cross-sectional study

Anahit Demirchyan iD, Sandra Dudareva, Serine Sahakyan, Lusine Aslanyan, Diana Muradyan, Lusine Musheghyan, Antons Mozalevskis, Narina Sargsyants, Gayane Ghukasyan, Varduhi Petrosyan

BMJ Open · 2024

DOI: 10.1136/bmjopen-2023-080281 ↗

Kurz gefasst

Querschnittstudie in der Zeitschrift BMJ Open, 2024. Verfasst von Anahit Demirchyan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Turpanjian College of Health Sciences, American University of Armenia, Yerevan, Armenia ademirch@aua.am. Hauptthemen laut MEDLINE: Hepatitis B, Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: World Health Organization, World Heath Organization Europe.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study sought to determine the prevalence and associated factors of hepatitis B virus (HBV) infection ever in life and chronic HBV infection in Armenia.

Design

A population-based cross-sectional seroprevalence study combined with a phone survey of tested individuals.

Setting

All administrative units of Armenia including 10 provinces and capital city Yerevan.

Participants

The study frame was the general adult population of Armenia aged ≥18 years. Primary and secondary outcome measures The participants were tested for anti-HBV core antibodies (anti-HBc) and HBV surface antigen (HBsAg) using third-generation enzyme immunoassays. In case of HBsAg positivity, HBV DNA and hepatitis D virus (HDV) RNA PCR tests were performed. Risk factors of HBV infection ever in life (anti-HBc positivity) and chronic HBV infection (HBsAg positivity) were identified through fitting logistic regression models.

Results

The seroprevalence study included 3838 individuals 18 years and older. Of them, 90.7% (3476 individuals) responded to the phone survey. The prevalence of anti-HBc positivity was 14.1% (95% CI 13.1% to 15.2%) and HBsAg positivity 0.8% (95% CI 0.5% to 1.1%). The viral load was over 10 000 IU/mL for 7.9% of HBsAg-positive individuals. None of the participants was positive for HDV. Risk factors for HBsAg positivity included less than secondary education (aOR=6.44; 95% CI 2.2 to 19.1), current smoking (aOR=2.56; 95% CI 1.2 to 5.6), and chronic liver disease (aOR=8.44; 95% CI 3.0 to 23.7). In addition to these, risk factors for anti-HBc positivity included age (aOR=1.04; 95% CI 1.04 to 1.05), imprisonment ever in life (aOR=2.53; 95% CI 1.41 to 4.56), and poor knowledge on infectious diseases (aOR=1.32; 95% CI 1.05 to 1.67), while living in Yerevan (vs provinces) was protective (aOR=0.74; 95% CI 0.59 to 0.93).

Conclusion

This study provided robust estimates of HBV markers among general population of Armenia. Its findings delineated the need to revise HBV testing and treatment strategies considering higher risk population groups, and improve population knowledge on HBV prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis BHepatitis B, ChronicAdultHumansAdolescentHepatitis B virusCross-Sectional StudiesHepatitis B Surface AntigensPrevalencePopulation GroupsSeroepidemiologic StudiesArmeniaHepatitis B AntibodiesDNA, Viral

Stichwörter der Autor:innen

EpidemiologyInfection controlPublic health

Substanzen

Hepatitis B Surface AntigensHepatitis B AntibodiesDNA, Viral

Autor:innen und Institutionen

  • Turpanjian College of Health Sciences, American University of Armenia, Yerevan, Armenia ademirch@aua.am.
  • Department for Infectious Disease Epidemiology, Robert Koch Institut, Berlin, Germany.
  • Turpanjian College of Health Sciences, American University of Armenia, Yerevan, Armenia.
  • Global HIV, Hepatitis and Sexually Transmitted Infections Programmes, World Health Organization, Geneva, Switzerland.
  • National Institute of Health named after academician Suren Avdalbekyan, Yerevan, Armenia.
  • World Health Organization Country Office in Armenia, Yerevan, Armenia.

ORCID-Profile: Anahit Demirchyan

Förderung

  • World Health Organization
  • World Heath Organization Europe

Zitieren

APA

Demirchyan, A., Dudareva, S., Sahakyan, S., Aslanyan, L., Muradyan, D., Musheghyan, L., Mozalevskis, A., Sargsyants, N., Ghukasyan, G., & Petrosyan, V. (2024). Prevalence of hepatitis B virus infection among general population of Armenia in 2021 and factors associated with it: a cross-sectional study. BMJ Open. https://doi.org/10.1136/bmjopen-2023-080281

Vancouver

Demirchyan A, Dudareva S, Sahakyan S, Aslanyan L, Muradyan D, Musheghyan L, et al. Prevalence of hepatitis B virus infection among general population of Armenia in 2021 and factors associated with it: a cross-sectional study. BMJ Open. 2024. doi:10.1136/bmjopen-2023-080281

BibTeX
@article{Demirchyan2024,
  author = {Demirchyan, Anahit and Dudareva, Sandra and Sahakyan, Serine and Aslanyan, Lusine and Muradyan, Diana and Musheghyan, Lusine and Mozalevskis, Antons and Sargsyants, Narina and Ghukasyan, Gayane and Petrosyan, Varduhi},
  title = {Prevalence of hepatitis B virus infection among general population of Armenia in 2021 and factors associated with it: a cross-sectional study},
  journal = {BMJ Open},
  year = {2024},
  doi = {10.1136/bmjopen-2023-080281}
}
Kostenlos starten →